Paloma Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Paloma Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-130,650	Closed	-$440K	–	2578
2020 Q2	$440K	Buy	+130,650	New	+$618K	0.01%	1285
2018 Q3	–	Sell	-50,599	Closed	-$493K	–	2036
2018 Q2	$493K	Buy	+50,599	New	+$519K	0.01%	1043
2016 Q3	–	Sell	-12,750	Closed	-$87K	–	2202
2016 Q2	$87K	Buy	+12,750	New	+$107K	﹤0.01%	2081

Other funds holding ZYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners's ZYNE Position: Q3 2020 in Review

Paloma Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 130,650 shares — an estimated $440K sold.

Paloma Partners first reported a position in ZYNE in Q2 2016 and held it in 3 quarters. The position peaked at $493K in Q2 2018. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

Paloma Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 130,650 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $440K.
Paloma Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2016 and held it in 3 quarters.
Paloma Partners's Zynerba Pharmaceuticals, Inc position peaked at $493K in Q2 2018.
66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.